Abstract
Background/Objectives:
To assess the distribution of interleukin (IL)-1β, IL-6, tumour necrosis factor (TNF)-α and C-reactive protein (CRP) according to the different definitions of metabolically healthy obesity (MHO).
Subjects/Methods:
A total of 881 obese (body mass index (BMI) ⩾30 kg/m2) subjects derived from the population-based CoLaus Study participated in this study. MHO was defined using six sets of criteria including different combinations of waist, blood pressure, total high-density lipoprotein cholesterol or low-density lipoprotein –cholesterol, triglycerides, fasting glucose, homeostasis model, high-sensitivity CRP, and personal history of cardiovascular, respiratory or metabolic diseases. IL-1β, IL-6 and TNF-α were assessed by multiplexed flow cytometric assay. CRP was assessed by immunoassay.
Results:
On bivariate analysis some, but not all, definitions of MHO led to significantly lower levels of IL-6, TNF-α and CRP compared with non-MH obese subjects. Most of these differences became nonsignificant after multivariate analysis. An posteriori analysis showed a statistical power between 9 and 79%, depending on the inflammatory biomarker and MHO definition considered. Further increasing sample size to overweight+obese individuals (BMI⩾25 kg/m2, n=2917) showed metabolically healthy status to be significantly associated with lower levels of CRP, while no association was found for IL-1β. Significantly lower IL-6 and TNF-α levels were also found with some but not all MHO definitions, the differences in IL-6 becoming nonsignificant after adjusting for abdominal obesity or percent body fat.
Conclusions:
MHO individuals present with decreased levels of CRP and, depending on MHO definition, also with decreased levels in IL-6 and TNF-α. Conversely, no association with IL-1β levels was found.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abbatecola AM, Ferrucci L, Grella R, Bandinelli S, Bonafè M, Barbieri M et al. (2004). Diverse effect of inflammatory markers on insulin resistance and insulin-resistance syndrome in the elderly. J Am Geriatr Soc 52, 399–404.
Aguilar-Salinas CA, García EG, Robles L, Riaño D, Ruiz-Gomez DG, Garcia-Ulloa AC et al. (2008). High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 93, 4075–4079.
Basu A, Devaraj S, Jialal I (2006). Dietary factors that promote or retard inflammation. Arterioscler Thromb Vasc Biol 26, 995–1001.
Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K et al. (2003). Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol 92, 522–528.
Coppack SW (2001). Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60, 349–356.
Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB et al. (2008). Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 5, e78.
Deurenberg P (2001). Universal cut-off BMI points for obesity are not appropriate. Br J Nutr 85, 135–136.
Di Renzo L, Bertoli A, Bigioni M, Del Gobbo V, Premrov MG, Calabrese V et al. (2008). Body composition and −174G/C interleukin-6 promoter gene polymorphism: association with progression of insulin resistance in normal weight obese syndrome. Curr Pharm Des 14, 2699–2706.
Dupont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL (2005). Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol 66, 175–191.
Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Sancho J, San Millán JL (2003). Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 46, 625–633.
Firmann M, Mayor V, Marques-Vidal P, Bochud M, Pécoud A, Hayoz D et al. (2008). The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord 8, 6.
Fischer CP, Berntsen A, Perstrup LB, Eskildsen P, Pedersen BK (2007). Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity. Scand J Med Sci Sports 17, 580–587.
Flower L, Ahuja RH, Humphries SE, Mohamed-Ali V (2000). Effects of sample handling on the stability of interleukin 6, tumour necrosis factor-alpha and leptin. Cytokine 12, 1712–1716.
Fröhlich M, Sund M, Löwel H, Imhof A, Hoffmeister A, Koenig W (2003). Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 24, 1365–1372.
Galland L (2010). Diet and inflammation. Nutr Clin Pract 25, 634–640.
Ghosh S, Meister D, Cowen S, Hannan WJ, Ferguson A (1997). Body composition at the bedside. Eur J Gastroenterol Hepatol 9, 783–788.
Karelis AD, Brochu M, Rabasa-Lhoret R (2004). Can we identify metabolically healthy but obese individuals (MHO)? Diab Metab 30, 569–572.
Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Prud’homme D et al. (2005). The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 90, 4145–4150.
Koster A, Stenholm S, Alley DE, Kim LJ, Simonsick EM, Kanaya AM et al. (2010). Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity (Silver Spring) 18, 2354–2356.
Lynch LA, O’Connell JM, Kwasnik AK, Cawood TJ, O’Farrelly C, O’Shea DB (2009). Are natural killer cells protecting the metabolically healthy obese patient? Obesity (Silver Spring) 17, 601–605.
Martin A, O’Sullivan AJ, Brown MA (2001). Body composition and energy metabolism in normotensive and hypertensive pregnancy. BJOG 108, 1263–1271.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419.
Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM et al. (2006). Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91, 2906–2912.
Messier V, Karelis AD, Prud’homme D, Primeau V, Brochu M, Rabasa-Lhoret R (2010). Identifying metabolically healthy but obese individuals in sedentary postmenopausal women. Obesity (Silver Spring) 18, 911–917.
Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS et al. (1997). Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82, 4196–4200.
Park HS, Park JY, Yu R (2005). Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diab Res Clin Pract 69, 29–35.
Payette C, Blackburn P, Lamarche B, Tremblay A, Bergeron J, Lemieux I et al. (2009). Sex differences in postprandial plasma tumor necrosis factor-alpha, interleukin-6, and C-reactive protein concentrations. Metabolism 58, 1593–1601.
Qi L, Zhang C, van Dam RM, Hu FB (2007). Interleukin-6 genetic variability and adiposity: associations in two prospective cohorts and systematic review in 26,944 individuals. J Clin Endocrinol Metab 92, 3618–3625.
Shin MJ, Hyun YJ, Kim OY, Kim JY, Jang Y, Lee JH (2006). Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int J Obes (Lond) 30, 1529–1534.
Simpson JA, Lobo DN, Anderson JA, Macdonald IA, Perkins AC, Neal KR et al. (2001). Body water compartment measurements: a comparison of bioelectrical impedance analysis with tritium and sodium bromide dilution techniques. Clin Nutr 20, 339–343.
Skeppholm M, Wallén NH, Blombäck M, Kallner A (2008). Can both EDTA and citrate plasma samples be used in measurements of fibrinogen and C-reactive protein concentrations? Clin Chem Lab Med 46, 1175–1179.
Steiner MC, Barton RL, Singh SJ, Morgan MD (2002). Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD. Eur Respir J 19, 626–631.
Stowe RP, Peek MK, Cutchin MP, Goodwin JS (2010). Plasma cytokine levels in a population-based study: relation to age and ethnicity. J Gerontol A Biol Sci Med Sci 65, 429–433.
Tsigos C, Kyrou I, Chala E, Tsapogas P, Stavridis JC, Raptis SA et al. (1999). Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. Metabolism 48, 1332–1335.
Velho S, Paccaud F, Waeber G, Vollenweider P, Marques-Vidal P (2010). Metabolically healthy obesity: different prevalences using different criteria. Eur J Clin Nutr 64, 1043–1051.
Vignali DA (2000). Multiplexed particle-based flow cytometric assays. J Immunol Methods 243, 243–255.
Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J et al. (2008). The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 168, 1617–1624.
Wolf HK, Kuulasmaa K, Tolonen H, Ruokokoski E (1998). Participation Rates, Quality of Sampling Frames and Sampling Fractions in the MONICA Surveys. WHO MONICA: Helsinki, Finland.
Acknowledgements
The CoLaus Study was supported by research grants from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, Switzerland, and the Fonds National Suisse de la recherche (Grant no: 33CSCO-122661). We would like to express our gratitude to the participants in the Lausanne CoLaus Study and to the investigators who have contributed to the recruitment, in particular Yolande Barreau, Anne-Lise Bastian, Binasa Ramic, Martine Moranville, Martine Baumer, Marcy Sagette, Jeanne Ecoffey and Sylvie Mermoud for data collection.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
DW is a full-time employee of GlaxoSmithKline (GSK), a pharmaceutical company. PV and GW received an unrestricted grant from GSK to build the CoLaus Study. The other authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on European Journal of Clinical Nutrition website
Supplementary information
Rights and permissions
About this article
Cite this article
Marques-Vidal, P., Velho, S., Waterworth, D. et al. The association between inflammatory biomarkers and metabolically healthy obesity depends of the definition used. Eur J Clin Nutr 66, 426–435 (2012). https://doi.org/10.1038/ejcn.2011.170
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ejcn.2011.170
Keywords
This article is cited by
-
Sarcopenia and Sarcopenic Obesity on Body Composition Analysis is a Significant Predictor of Mortality in Severe Acute Pancreatitis: A Longitudinal Observational Study
World Journal of Surgery (2023)
-
Relevance of body composition in phenotyping the obesities
Reviews in Endocrine and Metabolic Disorders (2023)
-
Comparing an adiposopathy approach with four popular classifications schemes to categorize the metabolic profile of postmenopausal women
Journal of Physiology and Biochemistry (2020)
-
Association of proinflammatory genes expression with serum interleukin 1β and free fatty acids in metabolically healthy and unhealthy abdominally obese individuals: a case-control study
BMC Immunology (2019)
-
Metabolically Healthy Obesity and Bariatric Surgery
Obesity Surgery (2019)